Astrana Health Inc (ASTH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Astrana Health Inc stock (ASTH) is currently trading at $24.48. Astrana Health Inc PE ratio is 52.67. Astrana Health Inc PS ratio (Price-to-Sales) is 0.42. Analyst consensus price target for ASTH is $36.00. WallStSmart rates ASTH as Underperform.
- ASTH PE ratio analysis and historical PE chart
- ASTH PS ratio (Price-to-Sales) history and trend
- ASTH intrinsic value — DCF, Graham Number, EPV models
- ASTH stock price prediction 2025 2026 2027 2028 2029 2030
- ASTH fair value vs current price
- ASTH insider transactions and insider buying
- Is ASTH undervalued or overvalued?
- Astrana Health Inc financial analysis — revenue, earnings, cash flow
- ASTH Piotroski F-Score and Altman Z-Score
- ASTH analyst price target and Smart Rating
Astrana Health Inc
📊 No data available
Try selecting a different time range
ASTH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Astrana Health Inc (ASTH)
ASTH trades 508% above its Graham fair value of $3.13, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Astrana Health Inc (ASTH) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Astrana Health Inc (ASTH) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
Revenue surging 42.90% year-over-year
Trading at 1.73x book value, attractively priced
60.66% held by institutions, strong professional interest
Supporting Valuation Data
Astrana Health Inc (ASTH) Areas to Watch (5)
Earnings declining -97.70%, profits shrinking
Very low returns on shareholder equity
Near-zero operating margins, business under pressure
Very thin margins, barely profitable
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Astrana Health Inc (ASTH) Detailed Analysis Report
Overall Assessment
This company scores 46/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth, Price/Book. Valuation metrics including Price/Sales (0.42), Price/Book (1.73) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 42.90%.
The Bear Case
The primary concerns are EPS Growth, Return on Equity, Operating Margin. Growth concerns include EPS Growth at -97.70%, which may limit upside. Profitability pressure is visible in Return on Equity at 4.49%, Operating Margin at 1.85%, Profit Margin at 0.71%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 4.49% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 42.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. EPS Growth and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ASTH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ASTH's Price-to-Sales ratio of 0.42x trades at a deep discount to its historical average of 3.45x (2th percentile). The current valuation is 98% below its historical high of 20.96x set in Dec 2017, and 21% above its historical low of 0.35x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.8x as trailing revenue scaled faster than the stock price.
Compare ASTH with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Astrana Health Inc (ASTH) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
Astrana Health Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 3.2B with 43% growth year-over-year. Profit margins are thin at 0.7%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 43% YoY, reaching 3.2B. This pace significantly outperforms most MEDICAL CARE FACILITIES peers.
ROE of 4.5% suggests the company isn't efficiently converting equity into profits.
Profit margin at 0.7% is thin. While this is common for high-growth companies, margins need to expand as growth naturally decelerates.
What to Watch Next
Margin expansion: can Astrana Health Inc push profit margins above 15% as the business scales?
Growth sustainability: can Astrana Health Inc maintain 43%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 52.7x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact Astrana Health Inc.
Bottom Line
Astrana Health Inc is a high-conviction growth story with revenue accelerating at 43% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.7% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:00:42 AM
About Astrana Health Inc(ASTH)
NASDAQ
HEALTHCARE
MEDICAL CARE FACILITIES
USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.